Compare CUBE & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUBE | TGTX |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.5B |
| IPO Year | 2004 | 2008 |
| Metric | CUBE | TGTX |
|---|---|---|
| Price | $42.10 | $49.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $44.00 | ★ $49.80 |
| AVG Volume (30 Days) | 2.1M | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 0.36 | 0.17 |
| Revenue | ★ $1,123,110,000.00 | $2,785,000.00 |
| Revenue This Year | $0.66 | $49.08 |
| Revenue Next Year | $2.82 | $26.69 |
| P/E Ratio | ★ $116.53 | $415.75 |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $35.09 | $25.37 |
| 52 Week High | $43.26 | $59.30 |
| Indicator | CUBE | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 43.86 |
| Support Level | $38.78 | $28.57 |
| Resistance Level | $42.71 | $58.08 |
| Average True Range (ATR) | 0.80 | 2.42 |
| MACD | 0.01 | -0.95 |
| Stochastic Oscillator | 63.41 | 38.37 |
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.